Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006493 · ClinicalTrials.gov registry record · Phase 2
Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia
A Phase 2 study, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006493: Completed Phase 2 study, sponsored by National Center for Research Resources (NCRR).
NCT00006493 is a Phase 2 study that has completed, run by National Center for Research Resources (NCRR). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006493, a Phase 2 study, has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this research is to study the effects of rosiglitazone, a drug usually taken for Type II diabetes, on HIV-associated hyperlipidemia. HIV-associated lipodystrophy is a medical condition characterized by gradual changes in the distribution of body fat. The body fat located in the extremities and face disappears while body fat around the abdomen and upper back increases. Certain biochemical changes occur in association with these changes in fat distribution. Lipid levels particularly serum triglycerides are increased. HDL, the "good cholesterol" is decreased. Higher than normal level of insulin or insulin resistance is also found in this condition. This latter condition is one of the hallmarks of Type II diabetes. The protease inhibitors, a class of HIV medications, are associated with the occurrence of HIV-associated lipodystrophy. It has been suggested that a biochemical pathway known as the peripheral peroxisomal activating receptor (PPAR) gamma system is blocked leading to the onset of this condition. Rosiglitazone is a new drug approved by the FDA in 1999 for the treatment of type II diabetes. It lowers blood sugar by improving insulin resistance, which as mentioned before, is the hallmark of Type II diabetes. It has also been noted to improve blood lipid levels. Rosiglitazone works by stimulating the PPAR gamma system. It is hoped that this drug can turn on the PPAR system and reverse the HIV-associated lipodystrophy syndrome.
Interventions
- DRUG Rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00006493 record still lists
NCT00006493 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Rosiglitazone is the first listed.
NCT00006493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006493 about?
NCT00006493 is a clinical study titled "Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia". The purpose of this research is to study the effects of rosiglitazone, a drug usually taken for Type II diabetes, on HIV-associated hyperlipidemia. HIV-associated lipodystrophy is a medical condition characterized by gradual changes in the distribution of body fat. The body fat located in the extrem...
What is the current status of trial NCT00006493?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00006493?
The interventions under investigation include: Rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00006493?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.